Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
ICU
Serious outcomes
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 budesonide studies
00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementLee33%0.67 [0.42-1.08]cases19/1,67495/5,345Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP33%0.67 [0.42-1.08]19/1,67495/5,34533% improvementAll studies45%0.55 [0.31-0.98]27/2,534116/6,21745% improvement3 budesonide COVID-19 studiesc19budesonide.com Sep 20, 2021Tau​2 = 0.08; I​2 = 27.1%; Z = 2.01Effect extraction pre-specifiedFavors budesonideFavors control 00.250.50.7511.251.51.752+Yu (RCT)39%0.61 [0.22-1.67]6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies39%0.61 [0.22-1.67]6/78710/79939% improvement1 budesonide COVID-19 mortality resultc19budesonide.com Sep 20, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.96Favors budesonideFavors control 00.250.50.7511.251.51.752+Yu (RCT)52%0.48 [0.23-1.01]10/77121/779Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment52%0.48 [0.23-1.01]10/77121/77952% improvementAll studies52%0.48 [0.23-1.01]10/77121/77952% improvement1 budesonide COVID-19 ICU resultc19budesonide.com Sep 20, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.93Favors budesonideFavors control 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 serious outcomesc19budesonide.com Sep 20, 2021Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65Effect extraction pre-specifiedFavors budesonideFavors control 00.250.50.7511.251.51.752+Lee33%0.67 [0.42-1.08]19/1,67495/5,345Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP33%0.67 [0.42-1.08]19/1,67495/5,34533% improvementAll studies33%0.67 [0.41-1.10]19/1,67495/5,34533% improvement1 budesonide COVID-19 case resultc19budesonide.com Sep 20, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.58Favors budesonideFavors control 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 Randomized Controlled Trialsc19budesonide.com Sep 20, 2021Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65Effect extraction pre-specifiedFavors budesonideFavors control 00.250.50.7511.251.51.752+Yu (RCT)39%0.61 [0.22-1.67]6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies39%0.61 [0.22-1.67]6/78710/79939% improvement1 budesonide COVID-19 RCT mortality resultc19budesonide.com Sep 20, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.96Favors budesonideFavors control 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 peer reviewed trialsc19budesonide.com Sep 20, 2021Tau​2 = 0.32; I​2 = 43.4%; Z = 1.65Effect extraction pre-specifiedFavors budesonideFavors control 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlRamakrishnan (RCT)90%0.10 [0.01-0.75]hosp./ER1/7010/69Ramakrishnan (RCT)67%0.33 [0.15-0.72]no recov.7/7021/69Yu (RCT)39%0.61 [0.22-1.67]death6/78710/799Yu (RCT)6%0.94 [0.44-1.98]ventilation13/77614/784Yu (RCT)52%0.48 [0.23-1.01]ICU10/77121/779Yu (RCT)25%0.75 [0.55-1.03]hosp./death72/787116/1,069Yu (RCT)17%0.83 [0.74-0.93]recov. time787 (n)1,069 (n)Lee33%0.67 [0.42-1.08]cases19/1,67495/5,345budesonide COVID-19 outcomesc19budesonide.com Sep 20, 2021Favors budesonideFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit